Immunotherapy study using CD160 for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests a treatment that activates the body’s immune cells (natural killer cells) using a target called CD160. It may help people with advanced melanoma, especially when the cancer can’t be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- Your cancer is stage III or IV and can’t be removed by surgery
- You are new to treatment or your melanoma has grown after one or more past treatments
- Your overall health score (ECOG) is 0 to 2 (you can still do daily activities fairly well)
- You agree to join the MelBase patient registry and sign informed consent
- You have health insurance coverage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This trial tests a new treatment for advanced melanoma that can be surgically removed. It combines your own immune cells (called gamma-delta T cells) with a drug (interferon or a PD-1 blocker) to see if it helps the body fight the cancer before and after surgery.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.